Susquehanna International Group, LLP Y M Abs Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

  • $560 Billion
  • Q3 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 07, 2024
BUY
$6.57 - $18.69 $176,076 - $500,892
26,800 New
26,800 $435,000
Q4 2022

Feb 14, 2023
SELL
$3.0 - $15.17 $140,100 - $708,439
-46,700 Reduced 80.94%
11,000 $53,000
Q3 2022

Nov 14, 2022
SELL
$13.96 - $19.67 $29,316 - $41,307
-2,100 Reduced 3.51%
57,700 $832,000
Q2 2022

Aug 15, 2022
BUY
$8.22 - $15.13 $234,270 - $431,205
28,500 Added 91.05%
59,800 $905,000
Q1 2022

May 16, 2022
BUY
$6.55 - $17.42 $205,015 - $545,246
31,300 New
31,300 $372,000

Others Institutions Holding YMAB

# of Institutions
106
Shares Held
24.5M
Call Options Held
40.3K
Put Options Held
400
View Full List

About Y-mAbs Therapeutics, Inc.

YMAB Quotes by TradingView
  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $356M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email